Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Exelixis Will Proceed With Development Of XL999 In NSCLC Based On Efficacy Data

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Clinical trial will initiate in the patient population this summer, with monitoring of cardiovascular events.

You may also be interested in...



GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate

Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.

GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate

Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.

Despite Enrollment Suspension, Exelixis Optimistic On XL999

Tyrosine kinase inhibitor is one of a dozen compounds GlaxoSmithKline can option.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS065944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By